Answers are grounded in this paper and cite their sources.
The rapid increase in resistance to antifungal drugs has been raised largely in Candida species due to continue and over utilization of available frontline drugs. To overcome this rising health care issue, it's necessary to identify a new and improved antifungal drug without causing any side effects than the existing drugs. In view of this, the present investigation was carried out in findings of the novel antifungal drug against pathogenic Candida species. The fungus Talaromyces islandicus VSGF1 was screened for the production of antifungal secondary metabolites through optimization of growth parameters under submerged fermentation by changing one variable at a time. The highest fungal biomass (1.9g/100ml of culture broth) with significant antifungal activity (15 mm zone of inhibition) was achieved in potato dextrose broth supplemented with 2% dextrose at pH6 and 26 OC temperature at stationary condition. A comparative antifungal activity was performed on frontline drugs of amphotericin B, fluconazole, ketoconazole, and nystatin along with extracellular and intracellular crude extracts of T. islandicus against eight Candida strains. Among the frontline drugs, only ketoconazole exhibited antifungal activity against tested Candida spp. and resistance has been observed by amphotericin B, fluconazole, and nystatin. Interestingly, both extracts of T. islandicus were found to possess significant and a broad spectrum of inhibitory activity against all tested Candida spp. This is the first report on this species from the genus Talaromyces that was used for the optimization of process parameters and contribution to the potential producers for antifungal secondary metabolites.
No takes yet. Share an insight, caveat, or question.
Kamradgi et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: